Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY3300054 + LY3321367 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3300054 | Lodapolimab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | LY3300054 (lodapolimab), is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29712568). | |
LY3321367 | LY 3321367|LY-3321367 | Immune Checkpoint Inhibitor 149 TIM-3 Antibody 9 | LY3321367, is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03099109 | Phase I | LY3321367 LY3300054 + LY3321367 | A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors | Completed | USA | ESP | 2 |